Abstract:Background: According to the latest revised National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (now known as the Alzheimer's Association) (NINCDS-ADRDA) diagnostic criteria for Alzheimer's disease dementia, the confidence in diagnosing mild cognitive impairment (MCI) due to Alzheimer's disease dementia is raised with the application of imaging biomarkers. These tests, added to core clinical criteria, might increase the sensitivity or specificity of a testing strategy. However, the accuracy of biomarkers in the diagnosis of Alzheimer's disease dementia and other dementias has not yet been systematically evaluated. A formal systematic evaluation of the sensitivity, specificity, and other properties of positron emission tomography (PET) imaging with the (11)C-labelled Pittsburgh Compound-B ((11)C-PIB) ligand was performed. Objectives: To determine the diagnostic accuracy of the (11)C- PIB-PET scan for detecting participants with MCI at baseline who will clinically convert to Alzheimer's disease dementia or other forms of dementia over a period of time. Search methods: The most recent search for this review was performed on 12 January 2013. We searched MEDLINE (OvidSP), EMBASE (OvidSP), BIOSIS Previews (ISI Web of Knowledge), Web of Science and Conference Proceedings (ISI Web of Knowledge), PsycINFO (OvidSP), and LILACS (BIREME). We also requested a search of the Cochrane Register of Diagnostic Test Accuracy Studies (managed by the Cochrane Renal Group).No language or date restrictions were applied to the electronic searches and methodological filters were not used so as to maximise sensitivity. Selection criteria: We selected studies that had prospectively defined cohorts with any accepted definition of MCI with baseline (11)C-PIB-PET scan. In addition, we only selected studies that applied a reference standard for Alzheimer's dementia diagnosis for example NINCDS-ADRDA or Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria. Data collection and analysis: We screened all titles generated by electronic database searches. Two review authors independently assessed the abstracts of all potentially relevant studies. The identified full papers were assessed for eligibility and data were extracted to create two by two tables. Two independent assessors performed quality assessment using the QUADAS 2 tool. We used the hierarchical summary receiver operating characteristic (ROC) model to produce a summary ROC curve. Main results: Conversion from MCI to Alzheimer's disease dementia was evaluated in nine studies. The quality of the evidence was limited. Of the 274 participants included in the meta-analysis, 112 developed Alzheimer's dementia. Based on the nine included studies, the median proportion converting was 34%. The studies varied markedly in how the PIB scans were done and interpreted.The sensitivities were between 83% and 100% while the specificities were between 46% and 88%. Because of the variation in thresholds and measures of (11)C-PIB amyloid retention, we did not calculate summary sensitivity and specificity. Although subject to considerable uncertainty, to illustrate the potential strengths and weaknesses of (11)C-PIB-PET scans we estimated from the fitted summary ROC curve that the sensitivity was 96% (95% confidence interval (CI) 87 to 99) at the included study median specificity of 58%. This equated to a positive likelihood ratio of 2.3 and a negative likelihood ratio of 0.07. Assuming a typical conversion rate of MCI to Alzheimer's dementia of 34%, for every 100 PIB scans one person with a negative scan would progress and 28 with a positive scan would not actually progress to Alzheimer's dementia.There were limited data for formal investigation of heterogeneity. We performed two sensitivity analyses to assess the influence of type of reference standard and the use of a pre-specified threshold. There was no effect on our findings. Authors' conclusions: Although the good sensitivity achieved in some included studies is promising for the value of (11)C-PIB-PET, given the heterogeneity in the conduct and interpretation of the test and the lack of defined thresholds for determination of test positivity, we cannot recommend its routine use in clinical practice.(11)C-PIB-PET biomarker is a high cost investigation, therefore it is important to clearly demonstrate its accuracy and standardise the process of the (11)C-PIB diagnostic modality prior to it being widely used.

Amyloid load but not regional glucose metabolism predicts conversion to Alzheimer’s dementia in a memory clinic population

The Value of FDG Combined with PiB PET in the Diagnosis of Patients with Cognitive Impairment in a Memory Clinic.

11C-PIB PET and 18F-FDG PET in patients with Alzheimer's disease and amnestic mild cognitive impairment

Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer’s Disease Progression

Amyloid Burden is Associated with Cognition in a Cross-Sectional and Short-Term Longitudinal Manner in Patients with Mild Cognitive Impairment

Cerebral glucose metabolism in Alzheimer's disease

P1‐007: Discrepant Diagnostic Classification with AV45‐PET and FDG‐PET of Clinically Diagnosed Alzheimer's Patients in the Alzheimer's Disease Neuroimaging Initiative

Impact of plasma glucose level on the pattern of brain FDG uptake and the predictive power of FDG PET in mild cognitive impairment

Clinical, Neuropsychological, and Neuroimaging Characteristics of Amyloid- Positive Vs. Amyloid-negative Patients with Clinically Diagnosed Alzheimer’s Disease and Amnestic Mild Cognitive Impairment

Amyloid PET in Dementia Syndromes: A Chinese Multicenter Study

DT‐01–06: Baseline FDG‐PET and Volumetric MRI Predicts Alzheimer's Disease Conversion from Mild Cognitive Impairment: an ADNI Study

Topographic extent of cerebral hypometabolism predicts time of conversion from aMCI to Alzheimer's disease: Data from the Alzheimer's Disease Neuroimaging Initiative

Discrepant diagnostic classification with AV45-PET and FDG-PET of clinically diagnosed Alzheimer's patients in the Alzheimer's Disease Neuroimaging Initiative

(11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)

F - FDG PET in Patients with Alzheimer's Disease and Amnestic Mild Cognitive Impairment ·neuroimaging Study of Alzheimer's Disease·

The Association Between Brain Metabolic Biomarkers Using 18F-FDG and Cognition and Vascular Risk Factors, as well as Its Usefulness in the Diagnosis and Staging of Alzheimer's Disease

Visual Assessment Versus Quantitative Assessment of 11C-PIB PET and 18F-FDG PET for Detection of Alzheimer's Disease

β-Amyloid is Associated with Aberrant Metabolic Connectivity in Subjects with Mild Cognitive Impairment

IC-P2-086: the Pattern of Cerebral Hypometablism in Amnestic Mild Cognitive Impairment and Its Relationship to Subsequent Conversion to Probable Alzheimer's Disease: Preliminary Findings from the Alzheimer's Disease Neuroimaging Initiative

Glucose Metabolism in Posterior Cingulate Cortex Has Supplementary Value to Predict the Progression of Cognitively Unimpaired to Dementia Due to Alzheimer's Disease: an Exploratory Study of 18F-FDG-PET.

18F-FDG PET can effectively rule out conversion to dementia and the presence of CSF biomarker of neurodegeneration: a real-world data analysis